ONT.L
ONT.L
GB00BP6S8Z30
OXFORD NANOPORE TECHNOLOGIES PL
Loading chart...

Company Profile

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

Related stocks

GNS.L
GNS.L • United Kingdom
GENUS PLC ORD 10P
2,280 GBp
1.97B USD 1Y -12.5%
IMCR
IMCR • United Kingdom
Immunocore Holdings plc
29.39 USD
1.51B USD 1Y -14.4%
BAVA.CO
BAVA.CO • Denmark
Bavarian Nordic A/S
236.8 DKK
2.67B USD 1Y -0.7%
ZEAL.CO
ZEAL.CO • Denmark
Zealand Pharma A/S
238 DKK
2.37B USD 1Y -53.5%
OXB.L
OXB.L • United Kingdom
OXFORD BIOMEDICA PLC ORD 50P
521 GBp
834.6M USD 1Y -20.8%
QURE
QURE • Netherlands
uniQure N.V.
22.59 USD
1.57B USD 1Y -62.4%
MEDCL.PA
MEDCL.PA • France
MEDINCELL S.A.
29.06 EUR
1.17B USD 1Y -11.3%
CAMX.ST
CAMX.ST • Sweden
Camurus AB
641 SEK
3.82B USD 1Y -8.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
58.3% p.a.
Max Drawdown (5Y)
-87.9%
Sharpe Ratio (5Y)
-0.36
Beta Factor
0.87
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (58.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -87.9% in the extended horizon.
ende